European Heart Journal Advance Access originally published online on October 11, 2005
European Heart Journal 2005 26(22):2351-2353; doi:10.1093/eurheartj/ehi574
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration
1Division of Cardiology, North York General Hospital, Toronto, Canada
2Division of Cardiology, McMaster University, Hamilton, Canada
3Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Canada
* Corresponding authors. S.V. Tel: +1 416 782 0092; fax: +1 416 782 0096. M.H.S. Tel: +1 416 730 0938; fax +1 416 229 6162.E-mail addresses: subodh.verma@sympatico.ca or Dr.Marty@bellnet.ca
This editorial refers to ‘Do angiotensin II receptor blockers increase the risk of myocardial infarction?’
by P. Verdecchia et al., on page 2381
| The first 150 words of the full text of this article appear below. |
Over the past year there has been fervent discussion and debate as to whether angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) offer similar coronary vascular protection.1–3 A widely held belief is that ARBs may be used interchangeably with ACE-Is, and that each regimen would offer a similar reduction in coronary vascular outcomes; a notion that argues against the concept of an ACE-I-specific, blood pressure-independent vascular protective effect relative to ARBs. The Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC), recently presented at the European Society of Hypertension (ESH) and provides important insight into this matter.4
The BPLTTC is a prestigious group of clinical trialists' that is conducting prospectively planned meta-analysis of blood pressure lowering trials.5 At the 15th meeting of the ESH, Dr Turnbull presented the largest and most comprehensive meta-regression analysis of ACE-Is and ARBs.4 In this analysis, the reduction in systolic blood pressure was plotted against
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Do angiotensin II receptor blockers increase the risk of myocardial infarction?
- Paolo Verdecchia, Fabio Angeli, Roberto Gattobigio, and Gian Paolo Reboldi
EHJ 2005 26: 2381-2386.[Abstract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  M. H. Strauss and A. S. Hall Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox Circulation, August 22, 2006; 114(8): 838 - 854. [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Strauss, E. Lonn, and S. Verma Angiotensin-II receptor blockers and coronary artery disease: 'presumed innocents': reply Eur. Heart J., June 2, 2006; 27(12): 1507 - 1508. [Full Text] [PDF]
|
|
|
|
|
|
M. Volpe, G. Tocci, and C. Savoia Angiotensin II receptor blockers and coronary artery disease: 'presumed innocents' Eur. Heart J., June 2, 2006; 27(12): 1506 - 1507. [Full Text] [PDF]
|
|